late breaking release on type 2 drug.....reason for the pop.
Excellent Q2 results
Rising with good volume.Fundamentals are looking strong compared with its peers. Higher rating at stockFA.
Yeah sure.Like the PBM's could possibly afford to drop NVO diabetes drugs from their lists. Fewer competitors would drive prices up, and leave less margin for skimming profits off of the health insurers.
@@@COPENHAGEN, Aug 2 (Reuters) - U.S. pharmacy benefit manager (PBM), CVS Health, said late Tuesday it had kept Novo Nordisk's key drugs on its 2018 list, removing some uncertainty over the U.S. market for the world's top insulin maker. The news came after Express Scripts said Monday it would exclude no new diabetes drugs in its 2018 list.
Two biggest U.S. drug purchasers keep key Novo Nordisk drugs on 2018 list
U.S. pharmacy benefit manager(PBM), CVS Health, said late Tuesday it had kept NovoNordisk's key drugs on its 2018 list, removing someuncertainty over the U.S. market for the world's top insulinmaker.
We always overestimate the change that will occur in the next two years and underestimate the change that will occur in the next ten. Don't let yourself be lulled into inaction. http://dataunion.tistory.com/12435
Novo Nordisk A_S NYSE $NVO Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is -0.8 In other words, the correlation coefficient of the other stocks
With An Uncertain Future, TherapeuticsMD Looks To New Prospects For Survival
TX-004HR received a CRL on May 5, 2017. Outcome of a Type A meeting with FDA to discuss the future course for TX-004HR is expected soon. The company is getting
(AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Down 3.2%? I guess NVO wasn't buying back shares today
This just got approved by fda
Do you think this thing is done selling? Showing us a buy signal now on NVO? Yo you should really check out awesome.stock.s, they seem on point with their stocks.
does this company send out 1099 or k1 form ? thanks
NVO Nonacog beta pegol $40.85 BLA filing announced May 16, 2016. PDUFA estimate May 16, 2017. Advisory Committee Meeting April 4, 2017.
Woohoo NVO beat and raise. Although, the profit forecast is still only a miserable couple of points on the plus side.
@@@@Novo Nordisk A/S (NVO) shares surged to a seven-month high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook. Novo Nordisk said sales for the three months ending in March rose 5% to Dkr28.5 billion ($4.2 billion), beating the FactSet compiled consensus of Drk27.9 billion. Operating profit for the quarter was also ahead of expectations, rising 10% to Dkr13.5 billion. The group also raised the lower portion of its full-year operating profit forecast range by around one percentage point to between -1% and +3% compared for a previous estimate of -2% to +3%.
Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost
Novo Nordisk shares surged to a year-to-date high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook.
Novo Nordisk A/S - Reduction of the share capital
Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.
The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
Received an alert this am about $NVO from http://thesubwaytrader.com/?s=NVO, you may want to take a look. Trading stocks day trading. Law of promotional tours: jet lag accumulates unit directionally towards maximum difficulty to perform.
The Subway Trader: Trading Stocks and Making Money
Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
So who is driving up NVO share price...earnings next week.